Correction: Gutierrez et al., "Ets-1 is required for the activation of VEGFR3 during latent Kaposi's sarcomaassociated herpesvirus infection of endothelial cells [Journal of Virology, 87, 12, (2013), (6758-6768)] doi: 10.1128/JVI.03241-12;Ets-1 is required for the activation of VEGFR3 during latent kaposi's sarcoma-associated herpesvirus infection of endothelial cells

Journal of Virology

Volumn 87, Issue 12, 2013, Pages 6758-6768

  Gutierrez, Kimberley D ^a   Morris, Valerie A ^a,c   Wu, David ^a   Barcy, Serge ^a,b   Lagunoff, Michael ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLICE INHIBITORY PROTEIN; GLYCOPROTEIN GP 130; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PODOPLANIN; TRANSCRIPTION FACTOR ETS 1; VASCULOTROPIN RECEPTOR 3;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FLICE INHIBITORY PROTEIN GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; INTRACELLULAR SIGNALING; KAPOSI SARCOMA; LATENT VIRUS INFECTION; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; NONHUMAN; PHENOTYPE; PODOPLANIN GENE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATOR GENE; SPINDLE CELL; TRANSCRIPTION FACTOR ETS 1 GENE; UPREGULATION; VASCULOTROPIN RECEPTOR 3 GENE; VIRUS ACTIVATION; VIRUS GENE;

HUMAN HERPESVIRUS 8;

EID: 84878586298     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01626-17     Document Type: Erratum

References (66)

1. Antman K, Chang Y. 2000. Kaposi's sarcoma. N. Engl. J. Med. 342:1027- 1038.
2. Ganem D. 2006. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu. Rev. Pathol. 1:273-296.
3. Senba M, Buziba N, Mori N, Morimoto K, Nakamura T. 2011. Increased prevalence of Kaposi's sarcoma-associated herpesvirus in the Kaposi's sarcoma-endemic area of western Kenya in 1981-2000. Acta Virol. 55:161-164.
4. Wahman A, Melnick SL, Rhame FS, Potter JD. 1991. The epidemiology of classic, African, and immunosuppressed Kaposi's sarcoma. Epidemiol. Rev. 13:178 -199.
5. Dimaio TA, Lagunoff M. 2012. KSHV induction of angiogenic and lymphangiogenic phenotypes. Front. Microbiol. 3:102.
6. Regezi JA, MacPhail LA, Daniels TE, DeSouza YG, Greenspan JS, Greenspan D. 1993. Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindleshaped endothelial cells. Am. J. Pathol. 143:240 -249.
7. Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D, Haase AT. 1997. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 71:715-719.
8. Jussila L, Valtola R, Partanen TA, Salven P, Heikkilä P, Matikainen MT, Renkonen R, Kaipainen A, Detmar M, Tschachler E, Alitalo R, Alitalo K. 1998. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-Cancer Res. 58:1599-1604.
9. Skobe M, Brown LF, Tognazzi K, Ganju RK, Dezube BJ, Alitalo K, Detmar M. 1999. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J. Investig. Dermatol. 113:1047-1053.
10. Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M, Pammer J, Stürzl M, Kerjaschki D, Alitalo K, Tschachler E. 1999. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab. Invest. 79:243-251.
11. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, Libermann T, Dezube BJ, Fingeroth JD, Detmar M. 2004. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcomaassociated herpesvirus. Nat. Genet. 36:683- 685.
12. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C. 2004. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat. Genet. 36:687- 693.
13. Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. 2005. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. U. S. A. 102:5570- 5575.
14. Chaudhary PM, Jasmin A, Eby MT, Hood L. 1999. Modulation of the NF-kappa B pathway by virally encoded death effector domainscontaining proteins. Oncogene 18:5738 -5746.
15. Dittmer D, Lagunoff M, Renne R, Staskus K, Haase A, Ganem D. 1998. A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J. Virol. 72:8309-8315.
16. Kedes DH, Lagunoff M, Renne R, Ganem D. 1997. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J. Clin. Invest. 100:2606 -2610.
17. Sadler R, Wu L, Forghani B, Renne R, Zhong W, Herndier B, Ganem D. 1999. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcomaassociated herpesvirus. J. Virol. 73:5722-5730.
18. Chandriani S, Ganem D. 2010. Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J. Virol. 84:5565- 5573.
19. Lagunoff M, Bechtel J, Venetsanakos E, Roy AM, Abbey N, Herndier B, McMahon M, Ganem D. 2002. De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J. Virol. 76:2440 -2448.
20. Carroll PA, Brazeau E, Lagunoff M. 2004. Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 328:7-18.
21. Oliver G, Alitalo K. 2005. The lymphatic vasculature: recent progress and paradigms. Annu. Rev. Cell Dev. Biol. 21:457- 483.
22. Oliver G, Harvey N. 2002. A stepwise model of the development of lymphatic vasculature. Ann. N. Y. Acad. Sci. 979:159 -165, 188-196.
23. Morris VA, Punjabi AS, Lagunoff M. 2008. Activation of Akt through gp130 receptor signaling is required for Kaposi's sarcoma-associated herpesvirus- induced lymphatic reprogramming of endothelial cells. J. Virol. 82:8771- 8779.
24. Morris VA, Punjabi AS, Wells RC, Wittkopp CJ, Vart R, Lagunoff M. 2012. The KSHV viral IL-6 homolog is sufficient to induce blood to lymphatic endothelial cell differentiation. Virology 428:112-120.
25. Fujimoto J, Aoki I, Toyoki H, Khatun S, Sato E, Sakaguchi H, Tamaya T. 2004. Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology 66:420-428.
26. Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kiriakidis S, Wernert N. 2008. The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. Mini Rev. Med. Chem. 8:1095-1105.
27. Nakayama T, Ito M, Ohtsuru A, Naito S, Nakashima M, Fagin JA, Yamashita S, Sekine I. 1996. Expression of the Ets-1 proto-oncogene in human gastric carcinoma: correlation with tumor invasion. Am. J. Pathol. 149:1931-1939.
28. Oikawa T. 2004. ETS transcription factors: possible targets for cancer therapy. Cancer Sci. 95:626-633.
29. Saeki H, Kuwano H, Kawaguchi H, Ohno S, Sugimachi K. 2000. Expression of ets-1 transcription factor is correlated with penetrating tumor progression in patients with squamous cell carcinoma of the esophagus. Cancer 89:1670 -1676.
30. Dittmer J. 2003. The biology of the Ets1 proto-oncogene. Mol. Cancer 2:29.
31. Fujimoto J, Aoki I, Toyoki H, Khatun S, Sato E, Tamaya T. 2003. Expression of ETS-1 related to angiogenesis in uterine endometrium during the menstrual cycle. J. Biomed. Sci. 10:320 -327.
32. Hahne JC, Okuducu AF, Fuchs T, Florin A, Wernert N. 2011. Identification of ETS-1 target genes in human fibroblasts. Int. J. Oncol. 38:1645- 1652.
33. Lian RH, Kumar V. 2002. Murine natural killer cell progenitors and their requirements for development. Semin. Immunol. 14:453- 460.
34. Sato Y. 2001. Role of ETS family transcription factors in vascular development and angiogenesis. Cell Struct. Funct. 26:19 -24.
35. Russell L, Garrett-Sinha LA. 2010. Transcription factor Ets-1 in cytokine and chemokine gene regulation. Cytokine 51:217-226.
36. Sato Y. 1998. Transcription factor ETS-1 as a molecular target for angiogenesis inhibition. Hum. Cell 11:207-214.
37. Sato Y, Teruyama K, Nakano T, Oda N, Abe M, Tanaka K, Iwasaka- Yagi C. 2001. Role of transcription factors in angiogenesis: Ets-1 promotes angiogenesis as well as endothelial apoptosis. Ann. N. Y. Acad. Sci. 947: 117-123.
38. Wei G, Srinivasan R, Cantemir-Stone CZ, Sharma SM, Santhanam R, Weinstein M, Muthusamy N, Man AK, Oshima RG, Leone G, Ostrowski MC. 2009. Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood 114:1123-1130.
39. Gegonne A, Punyammalee B, Rabault B, Bosselut R, Seneca S, Crabeel M, Ghysdael J. 1992. Analysis of the DNA binding and transcriptional activation properties of the Ets1 oncoprotein. New Biol. 4:512-519.
40. Lelievre E, Lionneton F, Soncin F, Vandenbunder B. 2001. The Ets family contains transcriptional activators and repressors involved in angiogenesis. Int. J. Biochem. Cell Biol. 33:391- 407.
41. Tian G, Erman B, Ishii H, Gangopadhyay SS, Sen R. 1999. Transcriptional activation by ETS and leucine zipper-containing basic helix-loophelix proteins. Mol. Cell. Biol. 19:2946 -2957.
42. Yang C, Shapiro LH, Rivera M, Kumar A, Brindle PK. 1998. A role for CREB binding protein and p300 transcriptional coactivators in Ets-1 transactivation functions. Mol. Cell. Biol. 18:2218 -2229.
43. Yordy JS, Muise-Helmericks RC. 2000. Signal transduction and the Ets family of transcription factors. Oncogene 19:6503- 6513.
44. Baillat D, Laitem C, Leprivier G, Margerin C, Aumercier M. 2009. Ets-1 binds cooperatively to the palindromic Ets-binding sites in the p53 promoter. Biochem. Biophys. Res. Commun. 378:213-217.
45. Dutta D, Ray S, Vivian JL, Paul S. 2008. Activation of the VEGFR1 chromatin domain: an angiogenic signal-ETS1/HIF-2alpha regulatory axis. J. Biol. Chem. 283:25404 -25413.
46. Robinson L, Panayiotakis A, Papas TS, Kola I, Seth A. 1997. ETS target genes: identification of egr1 as a target by RNA differential display and whole genome PCR techniques. Proc. Natl. Acad. Sci. U. S. A. 94:7170- 7175.
47. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE. 1998. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 58:5321-5325.
48. Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K, Shibuya M. 2000. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann. N. Y. Acad. Sci. 902:201-207.
49. Simon MP, Tournaire R, Pouyssegur J. 2008. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J. Cell. Physiol. 217:809-818.
50. Wakiya K, Begue A, Stehelin D, Shibuya M. 1996. A cAMP response element and an Ets motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene. J. Biol. Chem. 271:30823-30828.
51. Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M, Yoshizaki T. 2001. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am. J. Pathol. 159:27-33.
52. Murakami Y, Yamagoe S, Noguchi K, Takebe Y, Takahashi N, Uehara Y, Fukazawa H. 2006. Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx. J. Biol. Chem. 281:28113-28121.
53. Ye FC, Blackbourn DJ, Mengel M, Xie JP, Qian LW, Greene W, Yeh IT, Graham D, Gao SJ. 2007. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J. Virol. 81:3980 -3991.
54. Xie J, Ajibade A, Ye F, Kuhne K, Gao S. 2008. Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology 371:139 -154.
55. Yu F, Harada JN, Brown HJ, Deng H, Song MJ, Wu TT, Kato- Stankiewicz J, Nelson CG, Vieira J, Tamanoi F, Chanda SK, Sun R. 2007. Systematic identification of cellular signals reactivating Kaposi sarcoma- associated herpesvirus. PLoS Pathog. 3:e44. doi:10.1371/journal .ppat.0030044.
56. Vart RJ, Nikitenko LL, Lagos D, Trotter MW, Cannon M, Bourboulia D, Gratrix F, Takeuchi Y, Boshoff C. 2007. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res. 67:4042- 4051.
57. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. 2005. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 105:2510 -2518.
58. Alkharsah KR, Singh VV, Bosco R, Santag S, Grundhoff A, Konrad A, Stürzl M, Wirth D, Dittrich-Breiholz O, Kracht M, Schulz TF. 2011. Deletion of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein, vFLIP, from the viral genome compromises the activation of STAT1-responsive cellular genes and spindle cell formation in endothelial cells. J. Virol. 85:10375-10388.
59. Buggy Y, Maguire TM, McGreal G, McDermott E, Hill AD, O'Higgins N, Duffy MJ. 2004. Overexpression of the Ets-1 transcription factor in human breast cancer. Br. J. Cancer 91:1308 -1315.
60. Katayama S, Nakayama T, Ito M, Naito S, Sekine I. 2005. Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. Histol. Histopathol. 20:119 -126.
61. Nakayama T, Ito M, Ohtsuru A, Naito S, Sekine I. 2001. Expression of the ets-1 proto-oncogene in human colorectal carcinoma. Mod. Pathol. 14:415- 422.
62. DiMaio TA, Gutierrez KD, Lagunoff M. 2011. Latent KSHV infection of endothelial cells induces integrin beta3 to activate angiogenic phenotypes. PLoS Pathog. 7:e1002424. doi:10.1371/journal.ppat.1002424.
63. Guilluy C, Zhang Z, Bhende PM, Sharek L, Wang L, Burridge K, Damania B. 2011. Latent KSHV infection increases the vascular permeability of human endothelial cells. Blood 118:5344 -5354.
64. Wang L, Damania B. 2008. Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res. 68:4640- 4648.
65. Wu YH, Hu TF, Chen YC, Tsai YN, Tsai YH, Cheng CC, Wang HW. 2011. The manipulation of miRNA-gene regulatory networks by KSHV induces endothelial cell motility. Blood 118:2896 -2905.
66. Yoshimatsu Y, Yamazaki T, Mihira H, Itoh T, Suehiro J, Yuki K, Harada K, Morikawa M, Iwata C, Minami T, Morishita Y, Kodama T, Miyazono K, Watabe T. 2011. Ets family members induce lymphangiogenesis through physical and functional interaction with Prox1. J. Cell Sci. 124:2753-2762.